Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer

NCT01008566 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

NIH

Sponsor class

Conditions

Adult Hepatocellular Carcinoma
Advanced Adult Hepatocellular Carcinoma
Localized Non-Resectable Adult Liver Carcinoma
Recurrent Adult Liver Carcinoma

Interventions

BIOLOGICAL: Cixutumumab
OTHER: Laboratory Biomarker Analysis
DRUG: Sorafenib Tosylate

Sponsor

National Cancer Institute (NCI)